Reduction in mortality from breast cancer

British Medical Journal

Volumn 330, Issue 7485, 2005, Pages 205-206

  Jones, Alison L ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; FLUOROURACIL; METHOTREXATE; TAXANE DERIVATIVE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CANCER SURVIVAL; DIAGNOSTIC IMAGING; DRUG USE; EDITORIAL; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; MAMMOGRAPHY; OUTCOMES RESEARCH; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

EID: 13244290005     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.330.7485.205     Document Type: Editorial

References (12)

1. Sant M, Allemani C, Berrino F, Coleman MP, Aareleid T, Chaplain G, et al. Breast cancer survival in Europe and the United States. Cancer 2004;100:715-22.
2. Sainsbury R, Johnston C, Howard B. Effect on survival of delays in referral of patients with breast cancer symptoms: a retrospective analysis. Lancet 1999;353:1132-5.
3. Olsen AH, Njor S, Vejborg W, et al. Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study. BMJ 2005;330:220-2.
4. Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005;330:217-20.
5. Blanks RG, Moss SM, McGahan CE, Quinn MJ, Babb PJ. Effect of NHS breast screening programme on mortality from breast cancer in England and Wales 1990-8: comparison of observed with predicted mortality. BMJ 2000;321:665-9.
6. Early Breast Cancer Trials Collaborative Group. Polychemotherapy for early breast cancer: an overview of randomised trials. Lancet 1998;352:930-42.
7. Hebert-Croteau N, Brisson J, Latreille J, Rivard M, Abdelaziz N, Martin G. Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol 2004;22:3685-93.
8. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
9. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomised trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802.
10. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomised trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
11. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003;100:10393-8.
12. Van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.